<p><strong>Hereditary Transthyretin Amyloidosis</strong></p>
<p>Transthyretin amyloidosis (ATTR) is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body&rsquo;s organs and tissues. ATTR can be sub-classified as wild-type (wt) or hereditary, and the latter is then further sub-divided into familial amyloid polyneuropathy(FAP) and familial amyloid cardiomyopathy (FAC).</p>
<h2><strong><a href="https://www.delveinsight.com/report-store/hereditary-transthyretin-amyloidosis-hattr-epidemiology-forecast"><span style="text-decoration: underline;">Hereditary Transthyretin Amyloidosis Epidemiology</span></a> Segmentation in the 7MM</strong></h2>
<ul>
<li>Total diagnosed prevalent population of Hereditary Transthyretin Amyloidosis</li>
<li>Diagnosed prevalent cases of Hereditary Transthyretin Amyloidosis</li>
<li>Type-specific cases of Hereditary Transthyretin Amyloidosis</li>
<li>Stage-specific cases of familial amyloid polyneuropathy</li>
<li>New York Heart Association classification of familial amyloid polyneuropathy</li>
</ul>
<h3><strong>Hereditary Transthyretin Amyloidosis Epidemiological Insights Observed in the 7MM (2021)</strong></h3>
<p>The total prevalent cases of Hereditary Transthyretin Amyloidosis in the 7MM was approximately<strong> 24,000 in the year 2021</strong>.</p>
<h2><strong><a href="https://www.delveinsight.com/report-store/hereditary-transthyretin-amyloidosis-competitive-landscape-and-market"><span style="text-decoration: underline;">Hereditary Transthyretin Amyloidosis Market Insight</span></a>&nbsp;</strong></h2>
<p>The market size of Hereditary Transthyretin Amyloidosis in the 7MM is approximately <strong>USD- 1260 Million in the year 2021</strong>.</p>
<h3><strong>Hereditary Transthyretin Amyloidosis Market Strengths</strong></h3>
<ul>
<li>The upcoming pipeline also includes a gene therapy based on CRISPR technology, which is currently in early phase of development. If this therapy gets approved, it could provide a cure for hATTR.</li>
</ul>
<h3><strong>Hereditary Transthyretin Amyloidosis&nbsp; Market Opportunities</strong></h3>
<ul>
<li>Additional evidence for current and emerging therapies for patients with hATTR offers much-needed hope, along with a promise of better treatment, for this debilitating and life-threatening disease.</li>
</ul>
<p><strong>Hereditary Transthyretin Amyloidosis&nbsp; Market Drivers</strong></p>
<ul>
<li>Effective approved treatments</li>
<li>Potential of Emerging therapies</li>
<li>Genetic screening for hATTR</li>
<li>Registries to improve the understanding of hATTR</li>
<li>Incentives for Orphan Drugs</li>
</ul>
<p><strong>Hereditary Transthyretin Amyloidosis&nbsp; Market Barriers</strong></p>
<ul>
<li>Diagnostic barriers</li>
<li>Barriers to Access costly drugs</li>
<li>High cost of research and low return on investment</li>
</ul>
<h3><a href="https://www.delveinsight.com/report-store/hereditary-transthyretin-amyloidosis-hattr-pipeline-insight"><span style="text-decoration: underline;"><strong>Hereditary Transthyretin Amyloidosis Emerging drugs</strong></span></a></h3>
<p>The emerging drugs in the Hereditary Transthyretin Amyloidosis market are</p>
<ul>
<li>Eplontersen</li>
<li>Acoramidis (AG 10)</li>
<li>CRX-1008 (Tolcapone; SOM0226)</li>
<li>PRX004</li>
<li>NTLA-2001</li>
</ul>
<h3><strong>Hereditary Transthyretin Amyloidosis key players</strong></h3>
<p>The key players working in the&nbsp; Hereditary Transthyretin Amyloidosis market are</p>
<ul>
<li>Ionis Pharmaceuticals</li>
<li>AstraZeneca</li>
<li>Eidos Therapeutics</li>
<li>Corino Therapeutics</li>
<li>Prothena</li>
<li>Novo Nordisk</li>
<li>Intellia Therapeutics</li>
<li>Regeneron Pharmaceuticals</li>
</ul>

Hereditary Transthyretin Amyloidosis Market

Hereditary Transthyretin Amyloidosis Competitive and Market Infographics

Hereditary Transthyretin Amyloidosis Competitive and Market

Hereditary Transthyretin Amyloidosis Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.